Vivanza Biosci.

{
  "main_header": {
    "sid": 515837,
    "name": "Vivanza Biosci.",
    "stock_name": "Vivanza Biosci.",
    "full_name": "Vivanza Biosciences Ltd",
    "name_url": "stocks-analysis/vivanza-biosci",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1.95",
    "chg": -0.03,
    "chgp": "-1.52%",
    "dir": -1,
    "prev_price": "1.98",
    "mcapval": "8.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530057,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE984E01035",
    "curr_date": "Mar 13",
    "curr_time": "",
    "bse_nse_vol": "6.42 k",
    "exc_status": "Active",
    "traded_date": "Mar 13, 2026",
    "traded_date_str": "2026 03 13",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vivanza Biosciences Falls 3.43%: Downgrade and Valuation Shift Mark a Challenging Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-343-downgrade-and-valuation-shift-mark-a-challenging-week-3891829",
        "imagepath": "",
        "date": "2026-03-14 17:21:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Mar:</strong> Downgrade to Strong Sell rating announced</p>\n                    <p><strong>4 Mar:</strong> Stock price rises modestly to Rs.1.98 (+1.02%)</p>\n                    <p><strong>5 Mar:</strong> Valuation grade shifts from attractive to fair</p>\n                    <p><strong>6 Mar:</strong> Week closes at Rs.1.97 (-1.50%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.04</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.97</div><div class=\"stat-change negative\">-3.4..."
      },
      {
        "title": "Why is Vivanza Biosciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vivanza-biosciences-ltd-fallingrising-3881640",
        "imagepath": "",
        "date": "2026-03-10 01:13:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Downward Momentum Reflects in Price and Moving Averages</strong></p>\n<p>Vivanza Biosciences has been experiencing a sustained decline, with the stock price hitting a new 52-week low of ₹1.90 on the day. The recent two-day stretch has seen the stock lose approximately 3.5% in value, signalling persistent selling pressure. Furthermore, the share is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a bearish technical setup. This positioning suggests that short-term and long-term investor sentiment remains subdued, with no immediate technical support levels providing relief.</p>\n<p><strong>Comparative Performance Against Benchmarks and Sector</strong></p>\n<p>When analysing Vivanza Biosciences’ returns relative to t..."
      },
      {
        "title": "Vivanza Biosciences Ltd: Valuation Shift Signals Caution Amidst Weak Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shift-signals-caution-amidst-weak-returns-3872480",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_valuationdot_3872480.png",
        "date": "2026-03-05 08:00:46",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 1.02% to close at ₹1.98, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture that investors must carefully analyse in the context of sector peers and historical performance."
      },
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3865938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_mojoScore_3865938.png",
        "date": "2026-03-03 08:28:25",
        "description": "Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term performance, valuation metrics, and technical trends have prompted a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Vivanza Biosciences Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-a-detailed-analysis-of-the-rating-change-3857418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_mojoScore_3857418.png",
        "date": "2026-02-26 08:10:11",
        "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a modest improvement in technical indicators amid persistent fundamental challenges. The pharmaceutical and biotechnology company’s overall Mojo Score rose to 34.0, signalling a cautious shift in market sentiment as technical trends show signs of stabilisation despite ongoing financial headwinds."
      },
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3851068",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_mojoScore_3851068.png",
        "date": "2026-02-23 08:08:24",
        "description": "Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company continues to underperform its benchmark indices and peers, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Vivanza Biosciences Falls 2.33%: Valuation Shift and Mixed Fundamentals Shape Weekly Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-233-valuation-shift-and-mixed-fundamentals-shape-weekly-trend-3849904",
        "imagepath": "",
        "date": "2026-02-21 17:00:10",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Upgrade to Sell rating by MarketsMOJO on improved valuation and financial trends</p>\n                    <p><strong>16 Feb:</strong> Valuation shift signals renewed price attractiveness amid mixed fundamentals</p>\n                    <p><strong>20 Feb:</strong> Week closes at Rs.2.10, down 2.33% despite Sensex gains</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.15</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2.10</div><div class=\"stat-change negative\">-2.33%..."
      },
      {
        "title": "Vivanza Biosciences Ltd Upgraded to Sell on Improved Valuation and Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-on-improved-valuation-and-financial-trends-3841851",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_mojoScore_3841851.png",
        "date": "2026-02-16 08:22:19",
        "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a notable improvement in valuation metrics and technical indicators despite ongoing challenges in financial trends and quality parameters. The upgrade, effective from 13 February 2026, follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals."
      },
      {
        "title": "Vivanza Biosciences Ltd: Valuation Shift Signals Renewed Price Attractiveness Amid Mixed Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shift-signals-renewed-price-attractiveness-amid-mixed-fundamentals-3841562",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_valuationdot_3841562.png",
        "date": "2026-02-16 08:02:21",
        "description": "Vivanza Biosciences Ltd has witnessed a notable transformation in its valuation parameters, shifting from a previously risky profile to one that now appears attractive. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 173,
    "sid": "515837",
    "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-Feb-2026",
      "details": "In terms of regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed copy of newspaper advertisment published in English daily newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended December 31st 2025",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025",
      "datetime": "12-Feb-2026",
      "details": "Pursuant to Regulation 30 and Regulation 33 of SEBI (LODR) Regulations 2015 this is to inform you that the Board of Directors at its meeting held on Thursday 12th February 2026 has inter alia considered and approved the following: 1. The Un-audited Financial results Standalone and Consolidated as per indian accounting Standards (IND AS) along with the Limited review Report (s) issued by the Statutory Auditor for the Quarter and Nine Months ended 31st December 2025. The meeting of the Board of Directors of the Company commenced ot 2:30 P.M. and concluded at 3:00 P.M",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025",
      "datetime": "12-Feb-2026",
      "details": "Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR) Regulations 2015 this is to inform you that the Board of Directors at its meeting held on Thursday 12th February 2026 has inter alia considered and approved the following: 1. The Un-Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Limited Review Report(s) issued by the Statutory Auditor for the Quarter and Nine months ended 31st December 2025. The meeting of the Board of Directors of the Company commenced at 2:30 P.M. and concluded at 3:00 P.M.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23",
          "dt": "2023-03-24",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vivanza Biosciences Falls 3.43%: Downgrade and Valuation Shift Mark a Challenging Week

2026-03-14 17:21:51

Key Events This Week

2 Mar: Downgrade to Strong Sell rating announced

4 Mar: Stock price rises modestly to Rs.1.98 (+1.02%)

5 Mar: Valuation grade shifts from attractive to fair

6 Mar: Week closes at Rs.1.97 (-1.50%)

Week Open

Rs.2.04

Week Close

Rs.1.97

-3.4...

Read full news article

Why is Vivanza Biosciences Ltd falling/rising?

2026-03-10 01:13:37

Persistent Downward Momentum Reflects in Price and Moving Averages

Vivanza Biosciences has been experiencing a sustained decline, with the stock price hitting a new 52-week low of ₹1.90 on the day. The recent two-day stretch has seen the stock lose approximately 3.5% in value, signalling persistent selling pressure. Furthermore, the share is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a bearish technical setup. This positioning suggests that short-term and long-term investor sentiment remains subdued, with no immediate technical support levels providing relief.

Comparative Performance Against Benchmarks and Sector

When analysing Vivanza Biosciences’ returns relative to t...

Read full news article

Vivanza Biosciences Ltd: Valuation Shift Signals Caution Amidst Weak Returns

2026-03-05 08:00:46

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 1.02% to close at ₹1.98, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture that investors must carefully analyse in the context of sector peers and historical performance.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-03-03 08:28:25

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term performance, valuation metrics, and technical trends have prompted a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

Vivanza Biosciences Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change

2026-02-26 08:10:11

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a modest improvement in technical indicators amid persistent fundamental challenges. The pharmaceutical and biotechnology company’s overall Mojo Score rose to 34.0, signalling a cautious shift in market sentiment as technical trends show signs of stabilisation despite ongoing financial headwinds.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-02-23 08:08:24

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company continues to underperform its benchmark indices and peers, prompting a reassessment of its investment appeal.

Read full news article

Vivanza Biosciences Falls 2.33%: Valuation Shift and Mixed Fundamentals Shape Weekly Trend

2026-02-21 17:00:10

Key Events This Week

16 Feb: Upgrade to Sell rating by MarketsMOJO on improved valuation and financial trends

16 Feb: Valuation shift signals renewed price attractiveness amid mixed fundamentals

20 Feb: Week closes at Rs.2.10, down 2.33% despite Sensex gains

Week Open

Rs.2.15

Week Close

Rs.2.10

-2.33%...

Read full news article

Vivanza Biosciences Ltd Upgraded to Sell on Improved Valuation and Financial Trends

2026-02-16 08:22:19

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a notable improvement in valuation metrics and technical indicators despite ongoing challenges in financial trends and quality parameters. The upgrade, effective from 13 February 2026, follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Read full news article

Vivanza Biosciences Ltd: Valuation Shift Signals Renewed Price Attractiveness Amid Mixed Fundamentals

2026-02-16 08:02:21

Vivanza Biosciences Ltd has witnessed a notable transformation in its valuation parameters, shifting from a previously risky profile to one that now appears attractive. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the company’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News